EDIT Editas Medicine Inc

Price (delayed)

$12.23

Market cap

$839.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.73

Enterprise value

$651.76M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights
Editas Medicine's quick ratio has increased by 37% YoY and by 26% QoQ
The debt has contracted by 20% YoY and by 12% from the previous quarter
Editas Medicine's net income has decreased by 38% YoY but it has increased by 3.2% QoQ
EDIT's EPS is down by 24% year-on-year but it is up by 4.2% since the previous quarter
The revenue has dropped by 72% year-on-year
Editas Medicine's gross profit has plunged by 72% YoY

Key stats

What are the main financial stats of EDIT
Market
Shares outstanding
68.64M
Market cap
$839.48M
Enterprise value
$651.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.63
Price to sales (P/S)
32.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.25
Earnings
Revenue
$25.82M
EBIT
-$188.97M
EBITDA
-$183.52M
Free cash flow
-$173.69M
Per share
EPS
-$2.73
Free cash flow per share
-$2.54
Book value per share
$7.48
Revenue per share
$0.38
TBVPS
$9.1
Balance sheet
Total assets
$623.11M
Total liabilities
$110.35M
Debt
$23.16M
Equity
$512.76M
Working capital
$460.53M
Liquidity
Debt to equity
0.05
Current ratio
13.62
Quick ratio
13.42
Net debt/EBITDA
1.02
Margins
EBITDA margin
-710.9%
Gross margin
100%
Net margin
-721.6%
Operating margin
-724.4%
Efficiency
Return on assets
-26.9%
Return on equity
-32.9%
Return on invested capital
-45.3%
Return on capital employed
-32.2%
Return on sales
-732%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EDIT stock price

How has the Editas Medicine stock price performed over time
Intraday
-1.77%
1 week
1.16%
1 month
4.71%
1 year
-73.47%
YTD
-53.94%
QTD
-35.7%

Financial performance

How have Editas Medicine's revenue and profit performed over time
Revenue
$25.82M
Gross profit
$25.82M
Operating income
-$187.01M
Net income
-$186.29M
Gross margin
100%
Net margin
-721.6%
The revenue has dropped by 72% year-on-year
Editas Medicine's gross profit has plunged by 72% YoY
Editas Medicine's net income has decreased by 38% YoY but it has increased by 3.2% QoQ
EDIT's operating income is down by 29% year-on-year but it is up by 3.2% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation
P/E
N/A
P/B
1.63
P/S
32.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.25
EDIT's EPS is down by 24% year-on-year but it is up by 4.2% since the previous quarter
EDIT's P/B is 69% below its 5-year quarterly average of 5.4 and 60% below its last 4 quarters average of 4.2
EDIT's equity is down by 20% year-on-year and by 7% since the previous quarter
The revenue has dropped by 72% year-on-year
The P/S is 53% less than the last 4 quarters average of 70.6 and 48% less than the 5-year quarterly average of 63.4

Efficiency

How efficient is Editas Medicine business performance
Editas Medicine's ROA has decreased by 30% YoY and by 2.3% from the previous quarter
The ROE has decreased by 16% YoY and by 2.2% from the previous quarter
EDIT's return on sales is up by 4% since the previous quarter
EDIT's return on invested capital is up by 3.4% since the previous quarter

Dividends

What is EDIT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time
The current ratio has grown by 38% YoY and by 26% from the previous quarter
Editas Medicine's quick ratio has increased by 37% YoY and by 26% QoQ
The debt is 95% less than the equity
EDIT's equity is down by 20% year-on-year and by 7% since the previous quarter
The debt has contracted by 20% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.